• Citer

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab

par Lv, Shasha;Teugels, Erik ;Sadones, Jan;De Brakeleer, Sylvia;Duerinck, Johnny;Du Four, Stephanie;Michotte, Alex ;De Greve, Jacques;Neyns, Bart
Référence International journal of oncology, 41, 3, page (1029-1035)
Publication Publié, 2012-09

Article révisé par les pairs

• Détails
• Contenu

Titre:	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
Auteur:	Lv, Shasha; Teugels, Erik; Sadones, Jan; De Brakeleer, Sylvia; Duerinck, Johnny; Du Four, Stephanie; Michotte, Alex; De Greve, Jacques; Neyns, Bart
Informations sur la publication:	International journal of oncology, 41, 3, page (1029-1035)
Statut de publication:	Publié, 2012-09
Sujet CREF:	Cancérologie
Mots-clés:	Cetuximab
	Epithelial growth factor receptor amplification
	Epithelial growth factor receptor variant III
	Epithelial growth factor receptor variant IV
	Glioblastoma
	Isocitrate dehydrogenase 1
	Phosphatase and tensin homologue gene on chromosome 10
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1019-6439
	info:doi/10.3892/ijo.2012.1539
	info:scp/84865024576
	info:pmid/22752145